CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02616 CSTONE PHARMA-B

Pre-opening 04-01 09:06:09

3.310

+0.000

0.00%

High3.310	Low3.310	Vol0.00
Open3.310	D1 Closing3.310	Amplitude0.00%
Mkt Cap4.25B	Tradable Cap4.25B	Total Shares1.28B
T/O0.00	T/O Rate0.00%	Tradable Shares1.28B
P/B10.91	ROE-22.23%	EPS-0.08
52wk High3.890	52wk Low0.800	P/E-43.25
Dividend0.00	Div.Yield0.00	ROA-3.90%

暂无数据

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"CSTONE PHARMA-B","latestPrice":3.31,"timestamp":1743469200079,"preClose":3.31,"halted":0,"volume":0,"delay":0,"floatShares":1284191212,"shares":1284191212,"eps":-0.07653409487205422,"marketStatus":"Pre-opening","change":0,"latestTime":"04-01 09:06:07","open":3.31,"high":3.31,"low":3.31,"amount":0,"amplitude":0,"askPrice":3.39,"askSize":1000,"bidPrice":3.3,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.07653409487205422,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743471000000},"marketStatusCode":1,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":3.31,"openAndCloseTimeList":[[1743471000000,1743480000000],[1743483600000,1743494400000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616/wiki","defaultTab":"wiki","newsList":[{"id":"2522308806","title":"BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522308806","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522308806?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 20:39","pubTimestamp":1743079169,"startTime":"0","endTime":"0","summary":"BRIEF-CStone Pharmaceuticals Announces 2024 Annual Results And Recent Business ProgressMarch 27 (Reuters) - CStone Pharmaceuticals 2616.HK:CSTONE PHARMACEUTICALS ANNOUNCES 2024 ANNUAL RESULTS AND RECE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6BQ3WC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2522747883","title":"CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522747883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522747883?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:55","pubTimestamp":1743076548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6BQ3WC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2522374205","title":"Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374205?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:55","pubTimestamp":1743076500,"startTime":"0","endTime":"0","summary":"-      Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.-          EU & UK: Approved for first-line treatment of stage IV non-small cell lung cancer ; stage III NSCLC new indication application submitted to EMA.-     Global Partnerships: Three strategic partnerships across 40+ countries, to accelerate global commercialization.-      Localized Production: Approved for localized manufacturing in China, enhancing cost efficiency.-      Commercial Collaboration: Partnered with Hengrui to expand market access in China.-      Leading Position: Top 2 globally in clinical development for ROR1-targeted ADCs.-      Preclinical Differentiation: Superior tumor suppression vs. benchmarked competitors; potential first-in-class/best-in-class IO backbone therapy.-      More than 9 Differentiated Candidates: Focus on first-in-class/best-in-class assets, including multispecific antibodies and ADCs, with global rights and broad therapeutic potential.SUZHOU, Ch","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0957808578.USD","CEE","BK4232","SOC","BK4182","BK4097","BK1574","BK4231","BK4195","BK4017","BK4124","BK4585","ASH","LU0476273544.USD","LU0444973449.USD","LU0823414478.USD","LU1642822529.SGD","OS","ADC","BK4210","BK4541","BK4213","LU0444971666.USD","BK4588","LU2065732104.USD","02616","CPS","BK1161","SITC","BK4211","BE","LU0823414551.USD","BK4022","LU2249611893.SGD","CDE","R","LU2294711713.HKD","BK4570","LU2463526074.USD","ORR","PFS","HL","BK4109","BK4080","PRGS","LU1815336760.USD","LU2357125470.USD","LU0345780521.USD","LU2506951792.HKD"],"gpt_icon":0},{"id":"2522828341","title":"CStone Pharmaceuticals - Revenue Was RMB407.2 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522828341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522828341?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 16:32","pubTimestamp":1743064350,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA04P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2521796124","title":"CStone Seeks EU Approval for New Indication of Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521796124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521796124?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 16:28","pubTimestamp":1742804934,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (HKG:2616) submitted a Type II variation application to the European Medicines Agency (EMA) for a new indication of sugemalimab in stage III non-small cell lung cancer (NSCLC).T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1574","BK4156","BK1161"],"gpt_icon":0},{"id":"2521780747","title":"CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage Iii Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521780747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521780747?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 08:15","pubTimestamp":1742775305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4F329W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2520181703","title":"CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181703","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181703?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 17:05","pubTimestamp":1742375154,"startTime":"0","endTime":"0","summary":"As global markets grapple with inflation concerns and trade policy uncertainties, investors are seeking opportunities that can navigate these challenges. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. These stocks can offer surprising value and potential for significant returns when backed by solid financial foundations.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/materials/szse-002721/beijing-kingee-culture-development-shares/news/cstone-pharmaceuticals-leads-our-top-3-global-penny-stock-pi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","LU0516423091.SGD","LU1242518857.USD","LU0516422366.SGD","SG9999013460.SGD","LU0082770016.USD","LU0082770016.SGD","LU1242518931.SGD","LU0516423174.USD","SGXZ24219693.SGD","SGXZ43160589.SGD","LU0516422952.EUR","SGXZ58947870.SGD","SG9999000343.SGD","BIS.AU","LU0979878070.USD","SG9999014492.USD","LU0516422440.USD","SG9999000475.SGD","02616","LU0620787316.HKD","LU0164939612.USD","SG9999004360.SGD","SG9999013478.USD","BK1574","SG9999013486.USD","SG9999003826.SGD","BK7129","BK6504","SG9999016042.SGD","BK6065","SG9999014484.SGD","SGXZ27511609.SGD"],"gpt_icon":1},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","ADC","XJO.AU","02616","BK4080","BK7095","XAO.AU","BK4231","XKO.AU","BK1161","ADC.AU"],"gpt_icon":0},{"id":"2517976361","title":"CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976361?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 08:10","pubTimestamp":1741219803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA2T0MDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2516144536","title":"CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516144536","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516144536?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 13:43","pubTimestamp":1741067010,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  said the first patient was successfully dosed in the global multicenter Phase I clinical trial of its independently developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, without infusion reactions or other adverse events, according to a Tuesday filing with the Hong Kong Stock Exchange.CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4 to boost the immune response against tumors. It is designed to reinvigorate exhausted immune cells while neutralizing VEGF, making it a potential breakthrough for various cancers, including lung, liver, and ovarian cancer, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2516608698","title":"CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608698?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 08:10","pubTimestamp":1741047002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA2RYCFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2511624302","title":"There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2511624302","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511624302?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 07:43","pubTimestamp":1739576633,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( HKG:2616 ) shares have continued their recent momentum with a 28% gain in the last month...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/theres-no-escaping-cstone-pharmaceuticals-hkg2616-muted-reve-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02616"],"gpt_icon":0},{"id":"2510886958","title":"CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886958","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510886958?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 14:44","pubTimestamp":1739169872,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals'  sugemalimab has been included in the European Society for Medical Oncology  Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline, a Monday bourse filing said.Sugemalimab is recommended as a first-line combination therapy for both squamous and non-squamous non-small-cell lung cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2510001758","title":"CStone Announces Inclusion of Cejemly® (Sugemalimab) as a First-Line Combination Therapy for Nsclc in Esmo Guideline","url":"https://stock-news.laohu8.com/highlight/detail?id=2510001758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510001758?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 12:20","pubTimestamp":1739161203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA8QHRVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2510200185","title":"CStone Pharmaceuticals -  Announces Inclusion of Sugemalimab (Cejemly®) as First-Line Combination Therapy for Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2510200185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510200185?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 12:01","pubTimestamp":1739160073,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3OY2D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2508167781","title":"CStone Pharmaceuticals Partners Up with Latin American Pharmaceutical Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2508167781","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508167781?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 18:49","pubTimestamp":1738579775,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  agreed to give commercialization rights for its sugemalimab in ten Latin American countries to Latin American pharmaceutical company SteinCares, a Jan. 27 Hong Kong bourse filing said.Under the commercialization agreement, SteinCares will handle the regulatory affairs and commercialization activities in Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, and Ecuador.The company will receive upfront, regulatory, and commercial milestone payments, along with book revenue from the overseas partner through the supply of the said drug.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4117","BK1574","BK4107","AFG","BK1161","02616"],"gpt_icon":0},{"id":"2506931204","title":"CStone Pharmaceuticals - CStone and Steincares Enter Into Partnership to Market Sugemalimab in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2506931204","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506931204?lang=en_us&edition=full_marsco","pubTime":"2025-01-27 12:02","pubTimestamp":1737950552,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3OL0EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2493203038","title":"CStone Pharmaceuticals Submits Application for Solid Tumor Drug Trials in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2493203038","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493203038?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 10:50","pubTimestamp":1734922214,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  has submitted a clinical trial application in Australia for CS2009, a drug for solid tumors, according to a Monday filing with the Hong Kong bourse.CS2009 is a tri-specific antibody that targets PD-1, VEGFA, and CTLA-4 to treat major cancers. It has shown promise for treating various cancers, including lung, ovarian, kidney, cervical, liver, and stomach, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK1574","02616","XKO.AU","BK1161","XAO.AU"],"gpt_icon":0},{"id":"2493275237","title":"CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2493275237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493275237?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 08:00","pubTimestamp":1734912003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUA7YHZKB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2492195830","title":"CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2492195830","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492195830?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 10:06","pubTimestamp":1734573989,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  enrolled its first patient in its global multicenter phase 1B clinical trial for its CS5001 anti-tumor drug, according to a Thursday filing with the Hong Kong Exchange.The drug is indicated for anti-tumor activity in both solid tumors and lymphomas, showing \"robust\" anti-tumor activity in its Phase 1A trials, the filing said.Shares were down nearly 2% in morning trade Thursday.Price : $2.49, Change: $-0.070, Percent Change: -2.73%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK1161","BK4588","BK4526","02616","HKD","BK1574","BK4023"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.1197},{"period":"1month","weight":-0.035},{"period":"3month","weight":0.4391},{"period":"6month","weight":0.6974},{"period":"1year","weight":2.5213},{"period":"ytd","weight":0.4391}],"compareEarnings":[{"period":"1week","weight":-0.0329},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.1525},{"period":"6month","weight":0.0301},{"period":"1year","weight":0.3977},{"period":"ytd","weight":0.1525}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062298},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039956},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.10478},{"month":4,"riseRate":0.2,"avgChangeRate":-0.028106},{"month":5,"riseRate":0.4,"avgChangeRate":0.039766},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097121},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.016123},{"month":12,"riseRate":0.5,"avgChangeRate":0.028191}],"exchange":"SEHK","name":"CSTONE PHARMA-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSTONE PHARMA-B,02616,CSTONE PHARMA-B股票,CSTONE PHARMA-B股票老虎,CSTONE PHARMA-B股票老虎国际,CSTONE PHARMA-B行情,CSTONE PHARMA-B股票行情,CSTONE PHARMA-B股价,CSTONE PHARMA-B股市,CSTONE PHARMA-B股票价格,CSTONE PHARMA-B股票交易,CSTONE PHARMA-B股票购买,CSTONE PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}